[1] 熊丹.59例恶性血液病患者合并侵袭性真菌病的临床分析[J].中国医药科学,2016,6(5):18-25.
[2] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(第四次修订版)[J].中华内科杂志,2013,52(8):704-708.
[3] Freifeld AG,Bow EJ,Sepkowitz KA,et al.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the Infectious Diseases Society of America[J].Clin Infect Dis,2011,52(4):e56-93.
[4] 黄琰,吴隼,张媛,等.恶性血液病患者侵袭性肺部真菌感染的临床特点与治疗研究[J].中华医院感染学杂志,2016,26(7):1536-1538.
[5] Klepser M.The value of amphotericin B in the treatment of invasive fungal infections[J].J Crit Care,2011,26(2):225.e1-225.e10.
[6] Josilence CR,Herida RN.Review of fluconazole properties and analytical methods for its determination[J].Crit Rev Anal Chem,2011,4(2):124-132.
[7] 吴笑春,苏丹,周凡等.成年及危重患者肺部真菌感染治疗指南_续二[J].医药导报,2011,30(11):1-7.
[8] Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies:A retrospective study[J].Can J Infect Dis Med Microbiol,2014,25(6):299-304.
[9] 张淳嘉.41例恶性血液病患者合并侵袭性真菌感染的临床分析[D].广州:暨南大学,2012. |